Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide reduces insulin needs in type 1 diabetes
Last updated July 12, 2026
Key finding
Daily total insulin decreased from 53.6 [38.9, 80.9] to 46.7 [35.2, 68.0] by day 7.
The study investigated the impact of semaglutide on insulin needs in individuals with type 1 diabetes using pump therapy, revealing significant reductions in insulin requirements.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the impact of semaglutide on insulin needs in individuals with type 1 diabetes using pump therapy, revealing significant reductions in insulin requirements.
Clinical relevance
This study highlights the potential of semaglutide as a therapeutic option for individuals with type 1 diabetes, particularly those on pump therapy. By reducing insulin requirements, semaglutide could improve glycemic control and reduce the risk of hypoglycemia, ultimately enhancing patient quality of life and diabetes management.
Keep in mind
Effectiveness of semaglutide remains unclear due to lack of statistical significance. The sample size and demographic details were not specified. Results may not be generalizable to all populations with type 1 diabetes.
Published in
Journal Reference
Publication details and source links for this paper.
Melissa‐Rosina P, Michael AT, Ahmad H. Insulin Needs Decrease Rapidly with Semaglutide in Type 1 Diabetes on Pump Therapy. Diabetes, Obesity & Metabolism. 2025;28(1):427-433. doi:10.1111/dom.70213
Main Effects
Daily total insulin decreased by 6.9 units/day by day 7.
Daily bolus insulin decreased by 8.4 units/day by day 7.
Daily basal insulin decreased by 3.5 units/day by day 32.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide and Basal insulin dose, Daily bolus insulin requirements, Diabetic neuropathy incidence, and 5 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Basal insulin dose
- Daily bolus insulin requirements
- Diabetic neuropathy incidence
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 69
2
Related topics
8
Evidence pairs
157
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Insulin Resistance
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Neuropathy
Save evidence
Evidence topic
Adverse Events and Safety
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Daily bolus insulin requirements
Semaglutide → Daily bolus insulin requirements
Semaglutide → Daily bolus insulin requirements
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiabetic neuropathy incidence
Semaglutide → Diabetic neuropathy incidence
Semaglutide → Diabetic neuropathy incidence
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMedian increase in carbohydrate ratios by day 77
Semaglutide → Median increase in carbohydrate ratios by day 77
Semaglutide → Median increase in carbohydrate ratios by day 77
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMedian increase in correction factors by day 77
Semaglutide → Median increase in correction factors by day 77
Semaglutide → Median increase in correction factors by day 77
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMedian time spent in hypoglycemia rarely >4%
Semaglutide → Median time spent in hypoglycemia rarely >4%
Semaglutide → Median time spent in hypoglycemia rarely >4%
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerReduction in pre-programmed basal rates
Semaglutide → Reduction in pre-programmed basal rates
Semaglutide → Reduction in pre-programmed basal rates
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerTotal daily insulin dose
Semaglutide → Total daily insulin dose
Semaglutide → Total daily insulin dose
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Total daily insulin decreased by 6.9 units/day by day 7.
- Bolus insulin decreased by 8.4 units/day by day 7.
- Carbohydrate input reduced by 20 g/day by day 7.
Who this applies to
- Adults with type 1 diabetes on insulin pump therapy.
- Individuals seeking to optimize insulin management.
Keep in Mind
- The study may not represent all demographics of type 1 diabetes patients.
- Long-term effects of semaglutide were not evaluated.
- Further research is needed to confirm findings and assess safety.
Between the Lines
- Effectiveness of semaglutide remains unclear due to lack of statistical significance.
- The sample size and demographic details were not specified.
- Results may not be generalizable to all populations with type 1 diabetes.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Basal insulin dose, GLP-1 Receptor Agonists and Insulin Resistance.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Basal insulin dose
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceMedications
GLP-1 Receptor Agonists → Insulin Resistance
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Basal insulin dose Evidence Hub
All studies measuring Basal insulin dose
2 studies
outcome_hubMeasures Basal insulin dose as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
2 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Insulin Resistance Evidence Hub
All studies measuring Insulin Resistance
2 studies
outcome_hubMeasures Insulin Resistance as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Basal insulin dose
Intervention: SemaglutideOutcome: Basal insulin dose
2 results
All studies on Semaglutide and Total daily insulin dose
Intervention: SemaglutideOutcome: Total daily insulin dose
2 results
All studies on Semaglutide
Intervention: Semaglutide
2 results
All studies measuring Basal insulin dose
Outcome: Basal insulin dose
2 results
All studies measuring Total daily insulin dose
Outcome: Total daily insulin dose
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve insulin resistance?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Insulin Resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Total daily insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve neuropathy?
Moderate Evidence
GLP-1 Receptor Agonists appears to improve Neuropathy.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Diabetic neuropathy incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Semaglutide improve basal insulin dose?
Moderate Evidence
Semaglutide appears to improve Basal insulin dose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Basal insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Semaglutide improve median increase in carbohydrate ratios by day 77?
Emerging Evidence
Semaglutide appears to improve Median increase in carbohydrate ratios by day 77.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Median increase in carbohydrate ratios by day 77
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.